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Introduction
Two large paediatric studies are currently underway in
the U.S. to investigate efficacy and safety of MP29-02
(Dymista) in children, with a view to extending its
indication to those aged ≥6 yrs. In line with FDA
recommendations, these studies compare MP29-02 to
placebo. To mimic the clinical trial design of these
on-going pediatric studies, this meta-analysis assessed all
data available for moderate-to-severe SAR patients aged
12-17 years, who received either MP29-02 or placebo in
the same vehicle and device.
Methods
Data from 4 multi-centre, parallel-group, randomized,
double-blind, placebo-controlled, 14-day studies were
pooled. A total of 97 patients aged 12-17 yrs received
MP29-02 (a novel intranasal formulation of azelastine
hydrochloride and fluticasone propionate) 1 spray/nostril
bid (total daily dose: AZE 548µg; FP 200µg) and 112
patients received placebo spray 1 spray/nostril bid. The
primary efficacy variable was change from baseline over
14-days in reflective total nasal symptom score (rTNSS;
AM +PM; MAX=24), the sum of 4 symptom scores
for congestion, itching, rhinorrhoea and sneezing. Reflec-
tive total ocular symptom score (rTOSS; AM + PM;
Max = 18) was an important secondary endpoint.
Results
Patients aged 12-17 yrs treated with MP29-02 experi-
enced a 4.29 point mean improvement from baseline
(18.7 [SD 2.7]) in their rTNSS, significantly more the
2.06 point improvement from baseline (18.7 [SD 2.8])
observed in those treated with placebo (diff: 2.23; 95% CI:
3.23; 1.22; p<0.0001). Similarly, in this adolescent patient
population treatment with MP29-02 produced a signifi-
cant mean improvement in the rTOSS of 2.23 points
from baseline (11.2 [SD 4.4]) compared to 1.04 points
from baseline (10.9 [SD 4.0]) with placebo (diff: 1.19;
95% CI: 2.06, 0.32; p=0.0080).
Conclusion
These results show that adolescent SAR patients treated
with MP29-02 experience significant relief from both their
nasal and ocular symptoms. Similar beneficial effects may
be expected in pediatric patients.
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